Monitoring activity of fibrinolytic agents. A therapeutic challenge.

Shafer KE, Santoro SA, Sobel BE, Jaffe AS
Am J Med. 1984 76 (5): 879-86

PMID: 6232847 · DOI:10.1016/0002-9343(84)91003-9

The recognition that thrombolytic therapy may be beneficial for coronary thrombolysis has led to an increased use of plasminogen activators in critically ill patients, sometimes with inadequate monitoring. This review delineates the components of the fibrinolytic system, describes mechanisms of fibrinolysis, and presents practical guidelines for monitoring the use of activators of the system.

MeSH Terms (13)

Blood Coagulation Disorders Drug Administration Schedule Fibrin Fibrinogen Degradation Products Fibrinolysin Fibrinolysis Fibrinolytic Agents Humans Partial Thromboplastin Time Plasminogen Activators Prothrombin Time Streptokinase Thrombin Time Urokinase-Type Plasminogen Activator

Connections (2)

This publication is referenced by other Labnodes entities: